Improving diversity and inclusion in cancer prevention and therapy
Diversity and Inclusion in Research Underpinning Trials
This study is trying to find better ways to include diverse and underserved communities in cancer trials to ensure everyone has fair access to treatments and better health outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 644 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 3 sites (New York, New York and 2 other locations) |
| Trial ID | NCT05146297 on ClinicalTrials.gov |
What this trial studies
This initiative aims to address cancer disparities affecting diverse and underserved communities in New York City by enhancing diversity and inclusion in clinical trials. The project, known as DISRUPT, involves multidisciplinary teams from four institutions working together to implement innovative strategies at community, provider, and scientific levels. The study focuses on changing institutional policies and practices to improve participation rates among BIPOC patients facing treatment decisions for breast, liver, or prostate cancer. By creating a clinical trial match-list intervention, the research seeks to ensure equitable access to cancer therapies and improve outcomes for marginalized populations.
Who should consider this trial
Good fit: Ideal candidates include patients over 21 years old with invasive breast, liver, or prostate cancer who are facing a treatment decision.
Not a fit: Patients who are unable to give consent or do not have invasive breast or liver cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to improved cancer treatment outcomes for underrepresented populations.
How similar studies have performed: While the approach to enhancing diversity in clinical trials is gaining attention, this specific initiative represents a novel effort to systematically address disparities in cancer research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients \>21 years of age with invasive breast, lung or liver cancer, who face a treatment decision * patients of doctors who have consented to participate * able to give consent and speak either English or Spanish * For provider recruitment, oncologists, and advanced practitioners caring for patients with breast, lung, liver cancer including medical and surgical oncologists, interventional radiologists \& hepatologists will be eligible Exclusion Criteria: * Patients who are unable to give consent * unable to understand English or Spanish * lack of invasive breast/liver cancer * those who do not face an imminent treatment decision
Where this trial is running
New York, New York and 2 other locations
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (Recruiting)
- Herbert Irving Comprehensive Cancer Care Center — New York, New York, United States (Recruiting)
- Albert Einstein College of Medicine — The Bronx, New York, United States (Recruiting)
Study contacts
- Principal investigator: Nina Bickell — Icahn School of Medicine at Mount Sinai
- Study coordinator: Radhi Yagnik
- Email: radhi.yagnik@mountsinai.org
- Phone: 212-659-5933
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.